Recombinant human albumin comes from genetically engineered organisms, not from human blood. Scientists take the gene that codes for human serum albumin, insert it into a host organism’s DNA, and let that organism produce the protein. The three main production platforms are yeast, rice, and mammalian cells, with yeast being the most established and rice emerging as a promising alternative.
Why It Exists at All
Traditional human serum albumin is extracted from donated blood plasma. That process depends on a limited supply of human donors and carries a small but real risk of transmitting blood-borne pathogens. Global demand for albumin far exceeds what blood donation alone can supply, particularly in countries with less-developed blood banking systems. Recombinant production sidesteps both problems: the protein is grown in a controlled biological system with no human blood involved, eliminating pathogen risk entirely.
Yeast: The Most Established Platform
The most widely used host for recombinant human albumin is a yeast called Pichia pastoris, sometimes referred to as a methylotrophic yeast because it can feed on methanol as an energy source. Researchers insert the human albumin gene into the yeast’s genome, and the yeast cells then produce albumin as they grow in large fermentation tanks. Another yeast species, Saccharomyces cerevisiae (common baker’s yeast), has also been used.
The process is essentially industrial brewing with a pharmaceutical goal. Yeast cells are grown in nutrient-rich liquid media under carefully controlled conditions. In fed-batch fermentation runs with Pichia pastoris, researchers have achieved stable albumin yields of around 1.4 grams per liter of culture. One challenge is that the yeast can produce enzymes called proteases that break down the albumin during fermentation. This tends to happen when nitrogen runs low in the growth medium. Adjusting nitrogen and phosphorus levels in the medium prevents the problem.
Despite decades of development, yeast-derived recombinant albumin has not been widely commercialized for direct intravenous use in patients. One concern is that yeast proteins left over from manufacturing could trigger immune reactions. The product has found broad use in laboratory and industrial settings, though, particularly as a component in cell culture media and as a stabilizer in pharmaceutical formulations.
Rice: A Newer Bioreactor
Rice grains have emerged as a surprisingly effective way to produce recombinant human albumin. The approach uses transgenic rice plants (the species Oryza sativa) that have been engineered to express the human albumin gene specifically in their endosperm, the starchy interior of the grain where the plant naturally stores protein. A strong promoter sequence directs the albumin into the grain’s protein storage structures, so the rest of the plant remains unaffected.
Rice offers several practical advantages over yeast. Seeds can be harvested, dried, and stored for long periods without the protein degrading, which simplifies logistics. Production scales up the way any crop does: you plant more fields. And because rice has been a human food staple for thousands of years, rice proteins are well tolerated by the human body and pose a lower risk of triggering immune reactions than yeast or animal cell proteins.
The albumin purified from rice grains reaches purity levels above 99%, comparable to albumin derived from human plasma. A clinical trial published in the journal Gut tested rice-derived albumin in patients with decompensated liver cirrhosis, marking the first time a rice grain-based pharmaceutical protein was given to humans at high doses. The trial provided preliminary evidence that rice-derived albumin is both safe and effective, positioning it as a viable alternative to plasma-derived albumin for clinical use.
Other Host Organisms
Beyond yeast and rice, researchers have explored several other platforms. Mammalian cell lines can produce recombinant albumin, though they are expensive to maintain and raise their own contamination concerns. Transgenic potato and tobacco plants have also been tested as expression systems. None of these alternatives have advanced as far toward commercial or clinical use as yeast and rice.
From Gene to Finished Product
Regardless of the host organism, the starting point is the same: the human gene for serum albumin. This gene is packaged into a DNA construct along with regulatory sequences (promoters) that tell the host organism when and where to produce the protein. In rice, for example, the construct is introduced into the plant’s genome using a common soil bacterium called Agrobacterium tumefaciens as a delivery vehicle. In yeast, the gene is typically integrated directly into the organism’s chromosomes.
Once the host organism produces raw albumin, it has to be extracted and purified to pharmaceutical grade. The purification pipeline typically involves multiple rounds of chromatography, a technique that separates proteins based on their size, charge, or chemical properties. Ion exchange chromatography (which sorts proteins by electrical charge) is the workhorse step, often followed by size exclusion chromatography and ultrafiltration to remove remaining contaminants. The goal is to isolate albumin at 98% to 99% purity while removing any host cell proteins, DNA, or other unwanted material.
How It Compares to Blood-Derived Albumin
Structural studies comparing recombinant albumin from yeast with albumin purified from human plasma have found the two proteins to be structurally equivalent. They fold the same way and perform the same biological functions. One notable difference actually favors the recombinant version: it shows lower levels of structural variability than blood-derived albumin. That makes sense, because plasma albumin comes from thousands of different donors whose proteins carry slightly different modifications accumulated over a lifetime. Recombinant albumin, produced under uniform conditions, is more consistent batch to batch.
Where Recombinant Albumin Gets Used
Recombinant human albumin serves two broad categories of use. In laboratories and manufacturing, it replaces blood-derived albumin in cell culture media, vaccine stabilization, and drug formulation. Albumin acts as a carrier protein that keeps other molecules stable in solution, and it provides essential nutrients when cells are grown outside the body. Using a recombinant version eliminates the risk of introducing unknown blood-borne contaminants into these sensitive processes.
The clinical side is still developing. For decades, patients needing albumin infusions (for liver disease, burns, or major surgery) have received plasma-derived products. Recombinant versions are now entering this space, with rice-derived albumin leading the way in human trials. The recombinant albumin market was valued at roughly $150 billion in 2025 and is projected to grow to $260 billion by 2034, reflecting both expanding industrial demand and the push toward clinical adoption.